Company Logo

Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "AAV Vector Market: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the adeno-associated viral vector market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry.

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development.

Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA and ZOLGENSMA.

A number of adeno-associated viral vector-based therapies are also being evaluated in different clinical trials. In fact, it has been observed that clinical trials evaluating adeno-associated viral vector based therapies have increased at ~30% growth rate over the last few years. Further, it is worth mentioning that over 50 trials are expected to complete in the next three years.

In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors.

In fact, a number of these companies also offer advanced technology platforms, enabling the processing of adeno-associated viral vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. This is evident from the patents filed for protection of intellectual property related to such technologies.

Story continues

Additionally, multiple partnerships and collaborations have been established between the stakeholders in order to enhance development activity in this industry. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vector / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future.

Key Questions Answered

Which adeno-associated viral vector-based therapy candidates are present in the current development pipeline? Which disease indications are targeted by such products?

Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors?

Which type of adeno-associated viral vector related technologies are presently offered / being developed by the players in this domain?

Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors?

Which partnership models are commonly adopted by industry and non-industry stakeholders?

Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers?

What are the different initiatives undertaken by start-ups for the development of adeno-associated viral vectors in the recent past?

Which factors are likely to influence the decision of manufacturing the adeno-associated viral vector in-house or via outsourcing?

How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Chapter Overview3.2. Viral and Non-Viral Vectors3.2.1. Viral Vectors3.2.1.1. Adenovirus Vectors3.2.1.2. Adeno-Associated Viral Vectors3.2.1.3. Lentivirus Vectors3.2.1.4. Retrovirus Vectors3.2.1.5. Other Viral Vectors3.2.1.5.1. Alphavirus3.2.1.5.2. Foamy Virus3.2.1.5.3. Simian Virus3.2.1.5.4. Vaccinia Virus3.2.1.5.5. Chimeric Viral Vectors3.2.1.5.6. Herpes Simplex Virus3.2.1.5.7. Sendai Virus3.2.2. Non-Viral Vectors3.2.2.1. Plasmid DNA3.2.2.2. Oligonucleotides3.2.2.3. Liposomes, Lipoplexes, and Polyplexes3.2.2.4. Other Non-Viral Vectors3.3. Adeno-Associated Viral Vectors3.3.1. Structure and Design3.3.2. Adeno-Associated Viral Vector Life Cycle3.3.3. Applications of Adeno-Associated Viral Vectors3.3.3.1. Gene Therapy3.3.3.2. Vaccination3.3.4. Advantages of Adeno-Associated Viral Vectors3.3.5. Challenges Related to Adeno-Associated Viral Vectors3.4. Concluding Remarks

4. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPY: MARKET LANDSCAPE4.1. Chapter Overview4.2. Adeno-Associated Viral Vector Based Therapy: Overall Market Landscape4.2.1. Analysis by Phase of Development4.2.2. Analysis by Therapeutic Area(s)4.2.3. Analysis by Type of Gene / Molecule Targeted4.2.4. Analysis by Type of Therapy4.2.5. Analysis by Type of Gene Delivery Method Used4.2.6. Analysis by Route of Administration4.3. Adeno-Associated Viral Vector Based Therapy Candidates: Special Designations4.3.1. Analysis by Special Designation(s) Awarded4.4. Adeno-Associated Viral Vector Based Therapy: List of Developers4.4.1. Analysis by Year of Establishment4.4.2. Analysis by Company Size4.4.3. Analysis by Location of Headquarters4.4.4. Adeno-Associated Viral Vector Based Therapy: Leading Developers

5. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS: MARKET LANDSCAPE5.1. Chapter Overview5.2. Adeno-Associated Viral Vector Manufacturers: Overall Market Landscape5.2.1. Analysis by Year of Establishment5.2.2. Analysis by Company Size5.2.3. Analysis by Location of Headquarters5.2.4. Analysis by Type of Product(s) Manufactured5.2.5. Analysis by Location of Vector Manufacturing Facilities5.2.6. Analysis by Type of Manufacturer and Company Size5.2.7. Analysis by Scale of Operation5.2.8. Analysis by Location of Headquarters and Scale of Operation5.2.9. Analysis by Application Area(s)

6. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE6.1. Chapter Overview6.2. Adeno-Associated Viral Vector Manufacturing Technologies6.2.1. Analysis by Type of Technology6.2.2. Analysis by Scale of Operation6.2.3. Analysis by Application Area(s)6.2.4. Analysis by Therapeutic Area6.3. Adeno-Associated Viral Vector Technology: List of Developers6.3.1. Analysis by Year of Establishment6.3.2. Analysis by Company Size6.3.3. Analysis by Location of Headquarters6.3.4. Analysis by Company Size and Location of Headquarters6.3.5. Adeno-Associated Viral Vector Technology: Leading Developers

7. DRUG PROFILES7.1. Chapter Overview7.2. Marketed Gene Therapies7.2.1. LUXUTRNA (Spark Therapeutics)7.2.1.1. Company Overview7.2.1.2. Development Timeline7.2.1.3. Mechanism of Action7.2.1.4. Target Indication(s)7.2.1.5. Current Status of Development7.2.1.6. Manufacturing, Dosage and Sales7.2.2. ZOLGENSMA (Novartis)7.2.2.1. Company Overview7.2.2.2. Development Timeline7.2.2.3. Mechanism of Action7.2.2.4. Target Indication(s)7.2.2.5. Current Status of Development7.2.2.6. Manufacturing, Dosage and Sales7.3. Late Stage (Phase II/III and Above) Gene Therapies7.3.1. AGTC 501: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.2. LYS-SAF302: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.3. NFS-01: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.4. RGX-314: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.5. AMT-061: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.6. OAV-101: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.7. PF-06838435: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.8. PF-06939926: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.9. PF-07055480: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.10. SPK-8011: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.11. SRP-9001: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.12. BMN 270: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.13. Lumevoq (GS010): Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.14. PTC-AADC: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results

8. COMPANY PROFILES8.1. Chapter Overview8.2. Abeona Therapeutics8.2.1. Company Overview8.2.2. Financial Information8.2.3. AAV Vector Manufacturing related Capabilities8.2.4. Recent Developments and Future Outlook8.3 Aldevron (Acquired by Danaher)8.3.1. Company Overview8.3.2. Financial Information8.3.3. AAV Vector Manufacturing related Capabilities8.3.4. Recent Developments and Future Outlook8.4 Oxford BioMedica8.4.1. Company Overview8.4.2. Financial Information8.4.3. AAV Vector Manufacturing related Capabilities8.4.4. Recent Developments and Future Outlook8.5 Sanofi (CEPiA, Sanofi Pasteur, Genzyme)8.5.1. Company Overview8.5.2. Financial Information8.5.3. AAV Vector Manufacturing related Capabilities8.5.4. Recent Developments and Future Outlook8.6. WuXi AppTec8.6.1. Company Overview8.6.2. Financial Information8.6.3. AAV Vector Manufacturing related Capabilities8.6.4. Recent Developments and Future Outlook8.7. YPOSKESI8.7.1. Company Overview8.7.2. AAV Vector Manufacturing related Capabilities8.7.3. Recent Developments and Future Outlook

9. COMPANY COMPETITIVENESS ANALYSIS9.1. Chapter Overview9.2. Methodology and Key Parameters9.3. Adeno-Associated Viral Vector Manufacturers: In-house Manufacturers9.3.1. Players based in North America9.3.2. Players based in Europe9.4. Adeno-Associated Viral Vector Manufacturers: Contract Manufacturing Organizations9.4.1. Players based in North America9.4.2. Players based in Europe9.4.3. Players based in Asia-Pacific9.5. Adeno-Associated Viral Vector Manufacturers: Both In-House and Contract Manufacturing Organizations9.5.1. Players based in North America9.5.2. Players based in Europe9.5.3. Players based in Asia-Pacific

10. TECHNOLOGY COMPETITIVENESS ANALYSIS10.1. Chapter Overview10.2. Methodology and Key Parameters10.3. Adeno-Associated Viral Vector Technology Platforms10.3.1. Adeno-Associated Viral Vector Technology Platforms Developed by Companies10.3.2. Adeno-Associated Viral Vector Technology Platforms Developed by Companies based in Europe and Asia-Pacific

11. CLINICAL TRIAL ANALYSIS11.1. Chapter Overview11.2. Scope and Methodology11.3. Adeno-Associated Viral Vector Based Therapies: Clinical Trial Analysis

12. PARTNERSHIPS AND COLLABORATIONS12.1. Chapter Overview12.2. Partnership Models12.3. Adeno-Associated Viral Vector based Therapies: List of Partnerships and Collaborations12.4. Adeno-Associated Viral Vector Manufacturers: List of Partnerships and Collaborations

13. STRATEGIC PARTNER ANALYSIS

14. PATENT ANALYSIS

15. START-UP HEALTH INDEXING

16. OUTSOURCING: GO / NO-GO FRAMEWORK

17. MARKET SIZING AND OPPORTUNITY ANALYSIS

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/6ev168

Go here to read the rest:

Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of...